Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis out-licenses encorafenib to Array to make way for GSK oncology deal

Executive Summary

In order to satisfy conditions to close its acquisition of GlaxoSmithKline's oncology business (announced in April 2014), Novartis Pharma AG licensed Array BioPharma Inc. exclusive worldwide rights to develop, manufacture, and sell its Phase III BRAF inhibitor encorafenib (LGX818; NVPLGX818) for melanoma. Encorafenib is also in Phase I/II for colorectal cancer. Novartis will assign or license to Array patent and IP rights covering the compound, plus regulatory filings, technology, inventory, a companion diagnostic agreement (while not specified, this could be the November 2014 deal with Qiagen), and other contract rights.
Deal Industry
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Product or Technology Swap
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies